Hepatology
Conference Coverage
Frailty stratifies pediatric liver disease severity
The pediatric frailty score identified patients with end-stage liver disease with sensitivity of 47% and specificity of 98%.
From the Journals
Hepatitis Outlook: September 2016
A recent study suggested that hepatitis B virus–DNA testing should be considered routinely in monitoring drug-induced liver injury. Read about...
Conference Coverage
VIDEO: Harvoni shows safety, efficacy in adolescents for hepatitis C
One of the antiviral drug combinations that has revolutionized treatment of hepatitis C virus in adults has for the first time been shown safe and...
Article
Ombitasvir, paritaprevir, ritonavir, and dasabuvir in CKD patients with HCV
Twelve weeks of ombitasvir, paritaprevir, ritonavir, and dasabuvir (Viekira Pak) achieved sustained viral response in 90% of patients with...
From the Journals
Vitamin D deficiency linked to hepatitis B infection
More than half of hepatitis B patients were vitamin D deficient, and deficiency was associated with worse outcomes, in a Vietnamese study.
From the Journals
Nonalcoholic fatty liver disease estimated to cost $103 billion annually
Nonalcoholic fatty liver disease is estimated to affect more than 64 million people each year in the United States, leading to medical costs of...
From the Journals
Direct-acting antivirals: One of several keys to HCV eradication by 2030
Elimination of the public health threat posed by the hepatitis C virus (HCV) might seem impossible to achieve by 2030, but researchers in Italy...
News
Investigational HCV drug combo yields high SVR12 rates in compensated cirrhosis
A once-daily regimen of two investigational, direct-acting anti-HCV agents, ABT-493 and ABT-530, was well tolerated and achieved sustained viral...
News
Analysis yields ‘strong evidence’ for benefit of physical activity in NAFLD
Regular physical exercise significantly improved measures of nonalcoholic fatty liver disease independently of dietary changes, according to a...
From the Journals
Targeted HCV patients improve on sofosbuvir/daclatasvir combination
A combination of sofosbuvir/daclatasvir yielded sustained virological responses at 12 weeks after the last treatment in 95% of hepatitis C virus–...
News
Simple interventions markedly improve hepatitis care
Several simple, inexpensive operational interventions substantially improve care for viral hepatitis.